Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy
Identifieur interne : 001146 ( Main/Exploration ); précédent : 001145; suivant : 001147Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy
Auteurs : Inbal Braunstein [États-Unis] ; Victoria Werth [États-Unis]Source :
- Dermatologic Therapy [ 1396-0296 ] ; 2013-07.
English descriptors
- Teeft :
- Abnormality, Adverse effects, Animal models, Antenatal exposure, Antimalarial, Antimalarial drugs, Antiphospholipid antibody syndrome, Antirheumatic drugs, Arch dermatol, Arthritis rheum, Autoimmune, Autoimmune diseases, Autoimmune skin disease, Autoimmune skin diseases, Available data, Available safety data, Axis suppression, Azathioprine, Bowel disease, Braunstein werth, Breast milk, Calcineurin, Case reports, Chloroquine, Cleft, Clinical experience, Cochrane database syst, Congenital, Congenital abnormalities, Connective tissue diseases, Constitutional symptoms, Corticosteroid, Cutaneous lupus erythematosus, Cyclophosphamide, Danish study, Dapsone, Dermatol, Disease activity, Ductus arteriosus, Erythematosus, Fetal, Fetal growth restriction, Fetal outcomes, Fetus, Folic acid depletion, Gestational diabetes, Gestationis, Hemolytic anemia, Human experience, Hydroxychloroquine, Immunoglobulin, Infectious complications, Intrauterine growth retardation, Intravenous immunoglobulin, Ivig, Lactation, Limited data, Lupus, Lupus patients, Lupus pregnancy, Maintenance dose, Malaria prophylaxis, Maternal corticosteroid, Maternal disease, Medication, Methotrexate, Morphea, Mycophenolate mofetil, Neonatal, Neonatal lupus, Obstet gynecol, Ocular toxicity, Orofacial, Orofacial clefting, Orofacial clefts, Pemphigoid, Pemphigoid gestationis, Pemphigus, Pemphigus foliaceus, Pemphigus vulgaris, Prednisone, Prednisone dose, Pregnancy, Pregnancy category, Pregnancy class, Pregnancy outcomes, Pregnant patients, Pregnant women, Premature closure, Prenatal exposure, Preterm delivery, Refractory cases, Reproductive system, Retrospective studies, Rheumatic disease, Rheumatoid arthritis, Rheumatol, Rituximab, Skin diseases, Small amount, Small study, Steroid, Substantial data, Systematic review, Systemic, Systemic absorption, Systemic agent, Systemic corticosteroids, Systemic lupus erythematosus, Systemic sclerosis, Systemic therapy, Third trimester, Topical, Topical calcineurin inhibitors, Topical corticosteroids, Topical imiquimod, Topical psoralen, Topical steroids, Topical steroids calcineurin inhibitors, Victoria werth, Vulgaris, Weeks gestation, Werth, Young women.
Abstract
Autoimmune skin disease occurs in pregnancy, and treatment is often required to control both maternal disease and fetal outcomes. Here we present the available safety data in pregnancy and lactation for medications used to treat autoimmune skin diseases, including cutaneous lupus erythematosus, dermatomyositis, morphea and systemic sclerosis, pemphigus vulgaris, pemphigus foliaceus, and pemphigoid gestationis. A PubMed search of the English‐language literature using keywords, “pregnancy” “rheumatic disease,” and “connective tissue disease” was performed. Relevant articles found in the search and references were included. Reasonable evidence supports the careful and cautious use of topical steroids, topical calcineurin inhibitors, systemic corticosteroids, hydroxychloroquine, and azathioprine in pregnancy. Case reports or clinical experience suggest intravenous immunoglobulin, dapsone, phototherapy, rituximab, and plasmapheresis may be safe. Several treatment options exist for autoimmune skin disease in pregnancy and lactation, and should be considered when treating these patients.
Url:
DOI: 10.1111/dth.12076
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000069
- to stream Istex, to step Curation: 000069
- to stream Istex, to step Checkpoint: 000198
- to stream Main, to step Merge: 001147
- to stream Main, to step Curation: 001146
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy</title><author><name sortKey="Braunstein, Inbal" sort="Braunstein, Inbal" uniqKey="Braunstein I" first="Inbal" last="Braunstein">Inbal Braunstein</name></author><author><name sortKey="Werth, Victoria" sort="Werth, Victoria" uniqKey="Werth V" first="Victoria" last="Werth">Victoria Werth</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3FD61CCE52F8FCE3299FB338C8EC5A4F087C387C</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/dth.12076</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-5593RFGS-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000069</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000069</idno><idno type="wicri:Area/Istex/Curation">000069</idno><idno type="wicri:Area/Istex/Checkpoint">000198</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000198</idno><idno type="wicri:doubleKey">1396-0296:2013:Braunstein I:treatment:of:dermatologic</idno><idno type="wicri:Area/Main/Merge">001147</idno><idno type="wicri:Area/Main/Curation">001146</idno><idno type="wicri:Area/Main/Exploration">001146</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy</title><author><name sortKey="Braunstein, Inbal" sort="Braunstein, Inbal" uniqKey="Braunstein I" first="Inbal" last="Braunstein">Inbal Braunstein</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Dermatology, Philadelphia Veteran's Affairs Medical Center, Philadelphia</wicri:cityArea></affiliation><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>Perelman School of Medicine, Department of Dermatology, University of Pennsylvania, Pennsylvania</wicri:orgArea></affiliation></author><author><name sortKey="Werth, Victoria" sort="Werth, Victoria" uniqKey="Werth V" first="Victoria" last="Werth">Victoria Werth</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Dermatology, Philadelphia Veteran's Affairs Medical Center, Philadelphia</wicri:cityArea></affiliation><affiliation wicri:level="3"><country>États-Unis</country><placeName><settlement type="city">Philadelphie</settlement><region type="state">Pennsylvanie</region></placeName><wicri:orgArea>Perelman School of Medicine, Department of Dermatology, University of Pennsylvania, Pennsylvania</wicri:orgArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="sub">Treatment of Cutaneous Disorders of Pregnancy</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="354">354</biblScope><biblScope unit="page" to="363">363</biblScope><biblScope unit="page-count">10</biblScope><date type="published" when="2013-07">2013-07</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abnormality</term><term>Adverse effects</term><term>Animal models</term><term>Antenatal exposure</term><term>Antimalarial</term><term>Antimalarial drugs</term><term>Antiphospholipid antibody syndrome</term><term>Antirheumatic drugs</term><term>Arch dermatol</term><term>Arthritis rheum</term><term>Autoimmune</term><term>Autoimmune diseases</term><term>Autoimmune skin disease</term><term>Autoimmune skin diseases</term><term>Available data</term><term>Available safety data</term><term>Axis suppression</term><term>Azathioprine</term><term>Bowel disease</term><term>Braunstein werth</term><term>Breast milk</term><term>Calcineurin</term><term>Case reports</term><term>Chloroquine</term><term>Cleft</term><term>Clinical experience</term><term>Cochrane database syst</term><term>Congenital</term><term>Congenital abnormalities</term><term>Connective tissue diseases</term><term>Constitutional symptoms</term><term>Corticosteroid</term><term>Cutaneous lupus erythematosus</term><term>Cyclophosphamide</term><term>Danish study</term><term>Dapsone</term><term>Dermatol</term><term>Disease activity</term><term>Ductus arteriosus</term><term>Erythematosus</term><term>Fetal</term><term>Fetal growth restriction</term><term>Fetal outcomes</term><term>Fetus</term><term>Folic acid depletion</term><term>Gestational diabetes</term><term>Gestationis</term><term>Hemolytic anemia</term><term>Human experience</term><term>Hydroxychloroquine</term><term>Immunoglobulin</term><term>Infectious complications</term><term>Intrauterine growth retardation</term><term>Intravenous immunoglobulin</term><term>Ivig</term><term>Lactation</term><term>Limited data</term><term>Lupus</term><term>Lupus patients</term><term>Lupus pregnancy</term><term>Maintenance dose</term><term>Malaria prophylaxis</term><term>Maternal corticosteroid</term><term>Maternal disease</term><term>Medication</term><term>Methotrexate</term><term>Morphea</term><term>Mycophenolate mofetil</term><term>Neonatal</term><term>Neonatal lupus</term><term>Obstet gynecol</term><term>Ocular toxicity</term><term>Orofacial</term><term>Orofacial clefting</term><term>Orofacial clefts</term><term>Pemphigoid</term><term>Pemphigoid gestationis</term><term>Pemphigus</term><term>Pemphigus foliaceus</term><term>Pemphigus vulgaris</term><term>Prednisone</term><term>Prednisone dose</term><term>Pregnancy</term><term>Pregnancy category</term><term>Pregnancy class</term><term>Pregnancy outcomes</term><term>Pregnant patients</term><term>Pregnant women</term><term>Premature closure</term><term>Prenatal exposure</term><term>Preterm delivery</term><term>Refractory cases</term><term>Reproductive system</term><term>Retrospective studies</term><term>Rheumatic disease</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rituximab</term><term>Skin diseases</term><term>Small amount</term><term>Small study</term><term>Steroid</term><term>Substantial data</term><term>Systematic review</term><term>Systemic</term><term>Systemic absorption</term><term>Systemic agent</term><term>Systemic corticosteroids</term><term>Systemic lupus erythematosus</term><term>Systemic sclerosis</term><term>Systemic therapy</term><term>Third trimester</term><term>Topical</term><term>Topical calcineurin inhibitors</term><term>Topical corticosteroids</term><term>Topical imiquimod</term><term>Topical psoralen</term><term>Topical steroids</term><term>Topical steroids calcineurin inhibitors</term><term>Victoria werth</term><term>Vulgaris</term><term>Weeks gestation</term><term>Werth</term><term>Young women</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract">Autoimmune skin disease occurs in pregnancy, and treatment is often required to control both maternal disease and fetal outcomes. Here we present the available safety data in pregnancy and lactation for medications used to treat autoimmune skin diseases, including cutaneous lupus erythematosus, dermatomyositis, morphea and systemic sclerosis, pemphigus vulgaris, pemphigus foliaceus, and pemphigoid gestationis. A PubMed search of the English‐language literature using keywords, “pregnancy” “rheumatic disease,” and “connective tissue disease” was performed. Relevant articles found in the search and references were included. Reasonable evidence supports the careful and cautious use of topical steroids, topical calcineurin inhibitors, systemic corticosteroids, hydroxychloroquine, and azathioprine in pregnancy. Case reports or clinical experience suggest intravenous immunoglobulin, dapsone, phototherapy, rituximab, and plasmapheresis may be safe. Several treatment options exist for autoimmune skin disease in pregnancy and lactation, and should be considered when treating these patients.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region><settlement><li>Philadelphie</li></settlement></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Braunstein, Inbal" sort="Braunstein, Inbal" uniqKey="Braunstein I" first="Inbal" last="Braunstein">Inbal Braunstein</name></region><name sortKey="Braunstein, Inbal" sort="Braunstein, Inbal" uniqKey="Braunstein I" first="Inbal" last="Braunstein">Inbal Braunstein</name><name sortKey="Werth, Victoria" sort="Werth, Victoria" uniqKey="Werth V" first="Victoria" last="Werth">Victoria Werth</name><name sortKey="Werth, Victoria" sort="Werth, Victoria" uniqKey="Werth V" first="Victoria" last="Werth">Victoria Werth</name><name sortKey="Werth, Victoria" sort="Werth, Victoria" uniqKey="Werth V" first="Victoria" last="Werth">Victoria Werth</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001146 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001146 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3FD61CCE52F8FCE3299FB338C8EC5A4F087C387C
|texte= Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy
}}
| This area was generated with Dilib version V0.6.33. |  |